Cluster headache

Last updated

Cluster headache
Gray778.png
Trigeminal nerve
Specialty Neurology
Symptoms Recurrent, severe headaches on one side of the head, eye watering, stuffy nose [1]
Usual onset20 to 40 years old [2]
Duration15 min to 3 hrs [2]
TypesEpisodic, chronic [2]
CausesUnknown [2]
Risk factors Tobacco smoke, family history [2]
Diagnostic method Based on symptoms [2]
Differential diagnosis Migraine, trigeminal neuralgia, [2] other trigeminal autonomic cephalgias [3]
Prevention Verapamil, galcanezumab, oral glucocorticoids, steroid injections, civamide, [4]
Treatment Oxygen therapy, triptans [2] [4]
Frequency~0.1% at some point in time [5]

Cluster headache (CH) is a neurological disorder characterized by recurrent severe headaches on one side of the head, typically around the eye(s). [1] There is often accompanying eye watering, nasal congestion, or swelling around the eye on the affected side. [1] These symptoms typically last 15 minutes to 3 hours. [2] Attacks often occur in clusters which typically last for weeks or months and occasionally more than a year. [2]

Contents

The cause is unknown, [2] but is most likely related to dysfunction of the posterior hypothalamus. [6] Risk factors include a history of exposure to tobacco smoke and a family history of the condition. [2] Exposures which may trigger attacks include alcohol, nitroglycerin, and histamine. [2] They are a primary headache disorder of the trigeminal autonomic cephalalgias type. [2] Diagnosis is based on symptoms. [2]

Recommended management includes lifestyle adaptations such as avoiding potential triggers. [2] Treatments for acute attacks include oxygen or a fast-acting triptan. [2] [4] Measures recommended to decrease the frequency of attacks include steroid injections, galcanezumab, civamide, verapamil, or oral glucocorticoids such as prednisone. [6] [4] [7] Nerve stimulation or surgery may occasionally be used if other measures are not effective. [2] [6]

The condition affects about 0.1% of the general population at some point in their life and 0.05% in any given year. [5] The condition usually first occurs between 20 and 40 years of age. [2] Men are affected about four times more often than women. [5] Cluster headaches are named for the occurrence of groups of headache attacks (clusters). [1] They have also been referred to as "suicide headaches". [2]

Signs and symptoms

Cluster headaches are recurring bouts of severe unilateral headache attacks. [8] [9] The duration of a typical CH attack ranges from about 15 to 180 minutes. [2] About 75% of untreated attacks last less than 60 minutes. [10] However, women may have longer and more severe CH. [11]

The onset of an attack is rapid and typically without an aura. Preliminary sensations of pain in the general area of attack, referred to as "shadows", may signal an imminent CH, or these symptoms may linger after an attack has passed, or between attacks. [12] Though CH is strictly unilateral, there are some documented cases of "side-shift" between cluster periods, [13] or, rarely, simultaneous (within the same cluster period) bilateral cluster headaches. [14]

Pain

The pain occurs only on one side of the head, around the eye, particularly behind or above the eye, in the temple. The pain is typically greater than in other headache conditions, including migraines, and is usually described as burning, stabbing, drilling or squeezing. [15] While suicide is rare, those with cluster headaches may experience suicidal thoughts (giving the alternative name "suicide headache" or "suicidal headache"). [16] [17] The term "headache" does not adequately convey the severity of the condition; the disease may be the most painful condition known to medical science. [18] [19]

Dr. Peter Goadsby, Professor of Clinical Neurology at University College London, a leading researcher on the condition has commented:

"Cluster headache is probably the worst pain that humans experience. I know that's quite a strong remark to make, but if you ask a cluster headache patient if they've had a worse experience, they'll universally say they haven't. Women with cluster headache will tell you that an attack is worse than giving birth. So you can imagine that these people give birth without anesthetic once or twice a day, for six, eight, or ten weeks at a time, and then have a break. It's just awful." [20]

Other symptoms

The typical symptoms of cluster headache include grouped occurrence and recurrence (cluster) of headache attack, severe unilateral orbital, supraorbital and/or temporal pain. If left untreated, attack frequency may range from one attack every two days to eight attacks per day. [2] [21] Cluster headache attack is accompanied by at least one of the following autonomic symptoms: drooping eyelid, pupil constriction, redness of the conjunctiva, tearing, runny nose and less commonly, facial blushing, swelling, or sweating, typically appearing on the same side of the head as the pain. [21] Similar to a migraine, sensitivity to light (photophobia) or noise (phonophobia) may occur during a CH. Nausea is a rare symptom although it has been reported. [8]

Restlessness (for example, pacing or rocking back and forth) may occur. Secondary effects may include the inability to organize thoughts and plans, physical exhaustion, confusion, agitation, aggressiveness, depression, and anxiety. [16]

People with CH may dread facing another headache and adjust their physical or social activities around a possible future occurrence. Likewise they may seek assistance to accomplish what would otherwise be normal tasks. They may hesitate to make plans because of the regularity, or conversely, the unpredictability of the pain schedule. These factors can lead to generalized anxiety disorders, panic disorder, [16] serious depressive disorders, [22] social withdrawal and isolation. [23]

Cluster headaches have been recently associated with obstructive sleep apnea comorbidity. [24]

Recurrence

Cluster headaches may occasionally be referred to as "alarm clock headache" because of the regularity of their recurrence. CH attacks often awaken individuals from sleep. Both individual attacks and the cluster grouping can have a metronomic regularity; attacks typically striking at a precise time of day each morning or night. The recurrence of headache cluster grouping may occur more often around solstices, or seasonal changes, sometimes showing circannual periodicity. Conversely, attack frequency may be highly unpredictable, showing no periodicity at all. These observations have prompted researchers to speculate an involvement or dysfunction of the hypothalamus. The hypothalamus controls the body's "biological clock" and circadian rhythm. [25] [26] In episodic cluster headache, attacks occur once or more daily, often at the same time each day for a period of several weeks, followed by a headache-free period lasting weeks, months, or years. Approximately 10–15% of cluster headaches are chronic, with multiple headaches occurring every day for years, sometimes without any remission. [27]

In accordance with the International Headache Society (IHS) diagnostic criteria, cluster headaches occurring in two or more cluster periods, lasting from 7 to 365 days with a pain-free remission of one month or longer between the headache attacks may be classified as episodic. If headache attacks occur for more than a year without pain-free remission of at least three months, the condition is classified as chronic. [21] Chronic CH both occurs and recurs without any remission periods between cycles; there may be variation in cycles, meaning the frequency and severity of attacks may change without predictability for a period of time. The frequency, severity, and duration of headache attacks experienced by people during these cycles varies between individuals and does not demonstrate complete remission of the episodic form. The condition may change unpredictably from chronic to episodic and from episodic to chronic. [28]

Causes

PET1.jpg
PET2.jpg
PET3.jpg
Positron emission tomography (PET) shows brain areas being activated during pain.
VBM1.jpg
VBM2.jpg
VBM3.jpg
Voxel-based morphometry (VBM) shows brain area structural differences.

The specific causes and pathogenesis of cluster headaches are not fully understood. [6] The Third Edition of the International Classification of Headache disorders classifies CH as belonging to the trigeminal autonomic cephalalgias. [29]

Some experts consider the posterior hypothalamus to be important in the pathogenesis of cluster headaches. This is supported by a relatively high success ratio of deep-brain stimulation therapy on the posterior hypothalamic grey matter. [6]

Nerves

Therapies acting on the vagus nerve (CN X) and the greater occipital nerve have both shown efficacy in managing cluster headache, but the specific roles of these nerves are not well-understood. [6] Two nerves thought to play an important role in CH include the trigeminal nerve and the facial nerve. [30]

Genetics

Cluster headache may run in some families in an autosomal dominant inheritance pattern. [31] [32] People with a first degree relative with the condition are about 14–48 times more likely to develop it themselves, [1] and around 8 to 10% of persons with CH have a positive family history. [31] [33] Several studies have found a higher number of relatives affected among females. [33] Others have suggested these observations may be due to lower numbers of females in these studies. [33] Possible genetic factors warrant further research, current evidence for genetic inheritance is limited. [32]

Genes that are thought to play a role in the disease are the hypocretin/orexin receptor type 2 (HCRTR2), alcohol dehydrogenase 4(ADH4), G protein beta 3 (GNB3), pituitary adenylate cyclase-activating polypeptide type I receptor (ADCYAP1R1), and membrane metalloendopeptidase (MME) genes. [31]

Tobacco smoking

About 65% of persons with CH are, or have been, tobacco smokers. [1] Stopping smoking does not lead to improvement of the condition and CH also occurs in those who have never smoked (e.g. children); [1] it is thought unlikely that smoking is a cause. [1] People with CH may be predisposed to certain traits, including smoking or other lifestyle habits. [34]

Hypothalamus

A review suggests that the suprachiasmatic nucleus of the hypothalamus, which is the major biological clock in the human body, may be involved in cluster headaches, because CH occurs with diurnal and seasonal rhythmicity. [35]

Positron emission tomography (PET) scans indicate the brain areas which are activated during attack only, compared to pain free periods. These pictures show brain areas that are active during pain in yellow/orange color (called "pain matrix"). The area in the center (in all three views) is specifically activated during CH only. The bottom row voxel-based morphometry (VBM) shows structural brain differences between individuals with and without CH; only a portion of the hypothalamus is different. [36]

Diagnosis

Cluster-like head pain may be diagnosed as secondary headache rather than cluster headache. [21]

A detailed oral history aids practitioners in correct differential diagnosis, as there are no confirmatory tests for CH. A headache diary can be useful in tracking when and where pain occurs, how severe it is, and how long the pain lasts. A record of coping strategies used may help distinguish between headache type; data on frequency, severity and duration of headache attacks are a necessary tool for initial and correct differential diagnosis in headache conditions. [37]

Correct diagnosis presents a challenge as the first CH attack may present where staff are not trained in the diagnosis of rare or complex chronic disease. [10] Experienced ER staff are sometimes trained to detect headache types. [38] While CH attacks themselves are not directly life-threatening, suicide ideation has been observed. [16]

Individuals with CH typically experience diagnostic delay before correct diagnosis. [39] People are often misdiagnosed due to reported neck, tooth, jaw, and sinus symptoms and may unnecessarily endure many years of referral to ear, nose and throat (ENT) specialists for investigation of sinuses; dentists for tooth assessment; chiropractors and manipulative therapists for treatment; or psychiatrists, psychologists, and other medical disciplines before their headaches are correctly diagnosed. [40] Under-recognition of CH by health care professionals is reflected in consistent findings in Europe and the United States that the average time to diagnosis is around seven years. [41]

Differential

Cluster headache may be misdiagnosed as migraine or sinusitis. [41] Other types of headache are sometimes mistaken for, or may mimic closely, CH. Incorrect terms like "cluster migraine" confuse headache types, confound differential diagnosis and are often the cause of unnecessary diagnostic delay, [42] ultimately delaying appropriate specialist treatment.

Headaches that may be confused with CH include:

Prevention

Management for cluster headache is divided into three primary categories: abortive, transitional, and preventive. [48] Preventive treatments are used to reduce or eliminate cluster headache attacks; they are generally used in combination with abortive and transitional techniques. [8]

Verapamil

The recommended first-line preventive therapy is verapamil, a calcium channel blocker. [2] [49] Verapamil was previously underused in people with cluster headache. [8] Improvement can be seen in an average of 1.7 weeks for episodic CH and 5 weeks for chronic CH when using a dosage of ranged between 160 and 720 mg (mean 240 mg/day). [50] Preventive therapy with verapamil is believed to work because it has an effect on the circadian rhythm and on CGRPs. As CGRP-release is controlled by voltage-gated calcium channels. [50]

Glucocorticoids

Since these compounds are steroids, there is little evidence to support long-term benefits from glucocorticoids, [2] but they may be used until other medications take effect as they appear to be effective at three days. [2] They are generally discontinued after 8–10 days of treatment. [8] Prednisone is given at a starting dose of 60–80 milligrams daily; then it is reduced by 5 milligrams every day. Corticosteroids are also used to break cycles, especially in chronic patients. [51]

Surgery

Nerve stimulators may be an option in the small number of people who do not improve with medications. [52] [53] Two procedures, deep brain stimulation or occipital nerve stimulation, may be useful; [2] early experience shows a benefit in about 60% of cases. [54] It typically takes weeks or months for this benefit to appear. [53] A non-invasive method using transcutaneous electrical nerve stimulation (TENS) is being studied. [53]

A number of surgical procedures, such as a rhizotomy or microvascular decompression, may also be considered, [53] but evidence to support them is limited and there are cases of people whose symptoms worsen after these procedures. [53]

Other

Lithium, methysergide, and topiramate are recommended alternative treatments, [49] [55] although there is little evidence supporting the use of topiramate or methysergide. [2] [56] This is also true for tianeptine, melatonin, and ergotamine. [2] Valproate, sumatriptan, and oxygen are not recommended as preventive measures. [2] Botulinum toxin injections have shown limited success. [57] Evidence for baclofen, botulinum toxin, and capsaicin is unclear. [56]

Management

There are two primary treatments for acute CH: oxygen and triptans, [2] but they are underused due to misdiagnosis of the syndrome. [8] During bouts of headaches, triggers such as alcohol, nitroglycerine, and naps during the day should be avoided. [10]

Oxygen

Oxygen therapy may help to abort attacks, though it does not prevent future episodes. [2] Typically it is given via a non-rebreather mask at 12–15 liters per minute for 15–20 minutes. [2] One review found about 70% of patients improve within 15 minutes. [10] The evidence for effectiveness of 100% oxygen, however, is weak. [10] [58] Hyperbaric oxygen at pressures of ~2 times greater than atmospheric pressure may relieve cluster headaches. [58]

Triptans

The other primarily recommended treatment of acute attacks is subcutaneous or intranasal sumatriptan. [49] [59] Sumatriptan and zolmitriptan have both been shown to improve symptoms during an attack with sumatriptan being superior. [60] Because of the vasoconstrictive side-effect of triptans, they may be contraindicated in people with ischemic heart disease. [2] The vasoconstrictor ergot compounds may be useful, [10] but have not been well studied in acute attacks. [60]

Opioids

The use of opioid medication in management of CH is not recommended [61] and may make headache syndromes worse. [62] [63] Long-term opioid use is associated with well known dependency, addiction, and withdrawal syndromes. [64] Prescription of opioid medication may additionally lead to further delay in differential diagnosis, undertreatment, and mismanagement. [61]

Other

Intranasal lidocaine (sprayed in the ipsilateral nostril) may be an effective treatment with patient resistant to more conventional treatment. [11]

Octreotide administered subcutaneously has been demonstrated to be more effective than placebo for the treatment of acute attacks. [65]

Sub-occipital steroid injections have shown benefit and are recommended for use as a transitional therapy to provide temporary headache relief as more long term prophylactic therapies are instituted. [66]

Epidemiology

Cluster headache affects about 0.1% of the general population at some point in their life. [5] Males are affected about four times more often than females. [5] The condition usually starts between the ages of 20 and 50 years, although it can occur at any age. [1] About one in five of adults reports the onset of cluster headache between 10 and 19 years. [67]

History

The first complete description of cluster headache was given by the London neurologist Wilfred Harris in 1926, who named the disease migrainous neuralgia. [68] [69] [70] Descriptions of CH date to 1745 and probably earlier. [71]

The condition was originally named Horton's cephalalgia after Bayard Taylor Horton, a US neurologist who postulated the first theory as to their pathogenesis. His original paper describes the severity of the headaches as being able to take normal men and force them to attempt or die by suicide; his 1939 paper said:

"Our patients were disabled by the disorder and suffered from bouts of pain from two to twenty times a week. They had found no relief from the usual methods of treatment. Their pain was so severe that several of them had to be constantly watched for fear of suicide. Most of them were willing to submit to any operation which might bring relief." [72]

CH has alternately been called erythroprosopalgia of Bing, ciliary neuralgia, erythromelalgia of the head, Horton's headache, histaminic cephalalgia, petrosal neuralgia, sphenopalatine neuralgia, vidian neuralgia, Sluder's neuralgia, Sluder's syndrome, and hemicrania angioparalyticia. [73]

Society and culture

Robert Shapiro, a professor of neurology, says that while cluster headaches are about as common as multiple sclerosis with a similar disability level, as of 2013, the US National Institutes of Health had spent $1.872 billion on research into multiple sclerosis in one decade, but less than $2 million on CH research in 25 years. [74]

Research directions

Some case reports suggest that ingesting tryptamines such as LSD, psilocybin (as found in hallucinogenic mushrooms), or DMT can abort attacks and interrupt cluster headache cycles. [75] [76] The hallucinogen DMT has a chemical structure that is similar to the triptan sumatriptan, indicating a possible shared mechanism in preventing or stopping migraine and TACs. [51] In a 2006 survey of 53 individuals, 18 of 19 psilocybin users reported extended remission periods. The survey was not a blinded or a controlled study, and was "limited by recall and selection bias". [75] The safety and efficacy of psilocybin is currently being studied in cluster headache. [77] [78]

Fremanezumab, a humanized monoclonal antibody directed against calcitonin gene-related peptides alpha and beta, was in phase 3 clinical trials for CH, but stopped early due to a futility analysis demonstrating that a successful outcome was unlikely. [79] [80]

Related Research Articles

<span class="mw-page-title-main">Migraine</span> Disorder resulting in recurrent moderate-severe headaches

Migraine is a genetically influenced complex neurological disorder characterized by episodes of moderate-to-severe headache, most often unilateral and generally associated with nausea and light and sound sensitivity. Other characterizing symptoms may include nausea, vomiting, cognitive dysfunction, allodynia, and dizziness. Exacerbation of headache symptoms during physical activity is another distinguishing feature. Up to one-third of migraine sufferers experience aura: a premonitory period of sensory disturbance widely accepted to be caused by cortical spreading depression at the onset of a migraine attack. Although primarily considered to be a headache disorder, migraine is highly heterogenous in its clinical presentation and is better thought of as a spectrum disease rather than a distinct clinical entity. Disease burden can range from episodic discrete attacks, consisting of as little as several lifetime attacks, to chronic disease.

<span class="mw-page-title-main">Headache</span> Pain in the head, neck, or face

Headache, also known as cephalalgia, is the symptom of pain in the face, head, or neck. It can occur as a migraine, tension-type headache, or cluster headache. There is an increased risk of depression in those with severe headaches.

<span class="mw-page-title-main">Tension headache</span> Medical condition

Tension headache, stress headache, or tension-type headache (TTH), is the most common type of primary headache. The pain usually radiates from the lower back of the head, the neck, eyes or other muscle groups in the body typically affecting both sides of the head. Tension-type headaches account for nearly 90% of all headaches.

A medication overuse headache (MOH), also known as a rebound headache, usually occurs when painkillers are taken frequently to relieve headaches. These cases are often referred to as painkiller headaches. Rebound headaches frequently occur daily, can be very painful and are a common cause of chronic daily headache. They typically occur in patients with an underlying headache disorder such as migraine or tension-type headache that "transforms" over time from an episodic condition to chronic daily headache due to excessive intake of acute headache relief medications. MOH is a serious, disabling and well-characterized disorder, which represents a worldwide problem and is now considered the third-most prevalent type of headache. The proportion of patients in the population with Chronic Daily Headache (CDH) who overuse acute medications ranges from 18% to 33%. The prevalence of medication overuse headache (MOH) varies depending on the population studied and diagnostic criteria used. However, it is estimated that MOH affects approximately 1-2% of the general population, but its relative frequency is much higher in secondary and tertiary care.

<span class="mw-page-title-main">Visual snow syndrome</span> Visual impairment

Visual snow syndrome (VSS) is a form of visual hallucination that is characterized by the perception of small, flickering dots throughout the entire visual field. It is present in all conditions of illumination. The dots remain individual and do not clump together or change in size. Visual snow exists in one of two forms: the pulse type and the broadband type.

Occipital neuralgia (ON) is a painful condition affecting the posterior head in the distributions of the greater occipital nerve (GON), lesser occipital nerve (LON), third occipital nerve (TON), or a combination of the three. It is paroxysmal, lasting from seconds to minutes, and often consists of lancinating pain that directly results from the pathology of one of these nerves. It is paramount that physicians understand the differential diagnosis for this condition and specific diagnostic criteria. There are multiple treatment modalities, several of which have well-established efficacy in treating this condition.

Chronic paroxysmal hemicrania (CPH) is a severe debilitating unilateral headache usually affecting the area around the eye. It normally consists of multiple severe, yet short, headache attacks affecting only one side of the cranium. It is more commonly diagnosed in women than in men, but, unlike a migraine, has no neurological symptoms associated with it. CPH headaches are treated through the use of non-steroidal anti-inflammatory drugs, with indomethacin found to be usually effective in eliminating symptoms.

Hemicrania continua (HC) is a persistent unilateral headache that responds to indomethacin. It is usually unremitting, but rare cases of remission have been documented. Hemicrania continua is considered a primary headache disorder, meaning that another condition does not cause it.

Hypnic headaches are benign primary headaches that affect the elderly, with an average age of onset at 63 ± 11 years. They are moderate, throbbing, bilateral or unilateral headaches that wake the sufferer from sleep once or multiple times a night. They typically begin a few hours after sleep begins and can last from 15–180 min. There is normally no nausea, photophobia, phonophobia or autonomic symptoms associated with the headache. They commonly occur at the same time every night possibly linking the headaches with circadian rhythm, but polysomnography has recently revealed that the onset of hypnic headaches may be associated with REM sleep.

New daily persistent headache (NDPH) is a primary headache syndrome which can mimic chronic migraine and chronic tension-type headache. The headache is daily and unremitting from very soon after onset, usually in a person who does not have a history of a primary headache disorder. The pain can be intermittent, but lasts more than 3 months. Headache onset is abrupt and people often remember the date, circumstance and, occasionally, the time of headache onset. One retrospective study stated that over 80% of patients could state the exact date their headache began.

The International Classification of Headache Disorders (ICHD) is a detailed hierarchical classification of all headache-related disorders published by the International Headache Society. It is considered the official classification of headaches by the World Health Organization, and, in 1992, was incorporated into the 10th edition of their International Classification of Diseases (ICD-10). Each class of headache contains explicit diagnostic criteria—meaning that the criteria include quantities rather than vague terms like several or usually—that are based on clinical and laboratory observations.

Preventive treatment of migraine can be an important component of migraine management. Such treatments can take many forms, including everything from surgery, taking certain drugs or nutritional supplements, to lifestyle alterations such as increased exercise and avoidance of migraine triggers.

<span class="mw-page-title-main">Red ear syndrome</span> Medical condition

Red ear syndrome (RES) is a rare disorder of unknown etiology which was originally described in 1994. The defining symptom of red ear syndrome is redness of one or both external ears, accompanied by a burning sensation. A variety of treatments have been tried with limited success.

Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing is a rare headache disorder that belongs to the group of headaches called trigeminal autonomic cephalalgia (TACs). Symptoms include excruciating burning, stabbing, or electrical headaches mainly near the eye and typically these sensations are only on one side of the body. The headache attacks are typically accompanied by cranial autonomic signs that are unique to SUNCT. Each attack can last from five seconds to six minutes and may occur up to 200 times daily.

Occipital nerve stimulation (ONS), also called peripheral nerve stimulation (PNS) of the occipital nerves, is used to treat chronic migraine patients who have failed to respond to pharmaceutical treatments.

Migraine treatment may be either prophylactic (preventive) or abortive (rescue). Prevention is better than cure, so the ideal treatment goal is to prevent migraine attacks. Because migraine is an exceedingly complex condition, there are various preventive treatments which have their effect by disrupting different links in the chain of events that occur during a migraine attack. As rescue treatments also target and disrupt different processes occurring during migraine, these are summarized, with their relative merits and demerits.

<span class="mw-page-title-main">Orofacial pain</span> Medical condition

Orofacial pain is a general term covering any pain which is felt in the mouth, jaws and the face. Orofacial pain is a common symptom, and there are many causes.

Trigeminal autonomic cephalalgia (TAC) refers to a group of primary headaches that occurs with pain on one side of the head in the trigeminal nerve area and symptoms in autonomic systems on the same side, such as eye watering and redness or drooping eyelids.

<span class="mw-page-title-main">Recurrent painful ophthalmoplegic neuropathy</span> Medical condition

Recurrent painful ophthalmoplegic neuropathy (RPON), previously known as ophthalmoplegic migraine (OM), is a rare neurological disorder that is characterized by repeated headache attacks and reversible ipsilateral paresis of one or more ocular cranial nerves (CN). Oculomotor nerve (CNIII) is by far the most common cranial nerve involves in RPON, while abducens nerve (CNVI) and trochlear nerve (CNIV) involvements are also reported. Globally, RPON was estimated to have an annual incidence rate of 0.7 per million as of 1990, no further epidemiological studies have been conducted. It occurs more often in children and females.

<span class="mw-page-title-main">Christopher J. Boes</span> American neurologist and historian

Christopher J. Boes is an American neurologist and historian of medicine. He holds the titles of professor of neurology, professor of history of medicine, director of the W. Bruce Fye Center for the History of Medicine, at the Mayo Clinic, Rochester, Minnesota, and since 2022 is the Mayo Clinic Designated Institutional Official (DIO). His research focuses on the management of headache, including migraine and trigeminal autonomic cephalalgias. His work in the field of history of medicine includes research on Sir William Gowers, Sir William Osler, Bayard Taylor Horton, Mary Broadfoot Walker, Betty Clements and Harry Lee Parker.

References

  1. 1 2 3 4 5 6 7 8 9 Nesbitt, A. D.; Goadsby, P. J. (2012). "Cluster headache". BMJ. 344: e2407. doi:10.1136/bmj.e2407. PMID   22496300. S2CID   5479248.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 Weaver-Agostoni, J (2013). "Cluster headache". American Family Physician. 88 (2): 122–8. PMID   23939643. Archived from the original on 30 December 2019. Retrieved 24 July 2017.
  3. ↑ Rizzoli, P; Mullally, WJ (20 September 2017). "Headache". The American Journal of Medicine. 131 (1): 17–24. doi: 10.1016/j.amjmed.2017.09.005 . PMID   28939471.
  4. 1 2 3 4 Robbins, Matthew S.; Starling, Amaal J.; Pringsheim, Tamara M.; Becker, Werner J.; Schwedt, Todd J. (2016). "Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines". Headache. 56 (7): 1093–106. doi: 10.1111/head.12866 . PMID   27432623.
  5. 1 2 3 4 5 Fischera, M; Marziniak, M; Gralow, I; Evers, S (2008). "The Incidence and Prevalence of Cluster Headache: A Meta-Analysis of Population-Based Studies". Cephalalgia. 28 (6): 614–8. doi: 10.1111/j.1468-2982.2008.01592.x . PMID   18422717. S2CID   2471915.
  6. 1 2 3 4 5 6 Goadsby, Peter J. (2022). "Chapter 430". Harrison's Principles of Internal Medicine (21st ed.). McGraw Hill. ISBN   978-1264268504.
  7. ↑ Gaul, C; Diener, H; Müller, OM (2011). "Cluster Headache Clinical Features and Therapeutic Options". Deutsches Ärzteblatt International. 108 (33): 543–549. doi:10.3238/arztebl.2011.0543. PMC   3167933 . PMID   21912573.
  8. 1 2 3 4 5 6 Beck E, Sieber WJ, Trejo R (February 2005). "Management of cluster headache". American Family Physician (Review). 71 (4): 717–24. PMID   15742909. Archived from the original on 13 November 2015.
  9. ↑ Capobianco, David; Dodick, David (2006). "Diagnosis and Treatment of Cluster Headache". Seminars in Neurology. 26 (2): 242–59. doi:10.1055/s-2006-939925. PMID   16628535. S2CID   260319925.
  10. 1 2 3 4 5 6 Friedman, Benjamin Wolkin; Grosberg, Brian Mitchell (2009). "Diagnosis and Management of the Primary Headache Disorders in the Emergency Department Setting". Emergency Medicine Clinics of North America. 27 (1): 71–87, viii. doi:10.1016/j.emc.2008.09.005. PMC   2676687 . PMID   19218020.
  11. 1 2 Vollesen AL, Benemei S, Cortese F, Labastida-Ramírez A, Marchese F, Pellesi L, Romoli M, Ashina M, Lampl C, School of Advanced Studies of the European Headache Federation (EHF-SAS) (2018). "Migraine and cluster headache - the common link". The Journal of Headache and Pain . 19 (1): 89. doi: 10.1186/s10194-018-0909-4 . PMC   6755613 . PMID   30242519.
  12. ↑ Marmura, Michael J; Pello, Scott J; Young, William B (2010). "Interictal pain in cluster headache". Cephalalgia. 30 (12): 1531–4. doi:10.1177/0333102410372423. PMID   20974600. S2CID   153838.
  13. ↑ Meyer, Eva Laudon; Laurell, Katarina; Artto, Ville; Bendtsen, Lars; Linde, Mattias; Kallela, Mikko; Tronvik, Erling; Zwart, John-Anker; Jensen, Rikke M.; Hagen, Knut (2009). "Lateralization in cluster headache: A Nordic multicenter study". The Journal of Headache and Pain . 10 (4): 259–63. doi:10.1007/s10194-009-0129-z. PMC   3451747 . PMID   19495933.
  14. ↑ Bahra, A; May, A; Goadsby, PJ (2002). "Cluster headache: A prospective clinical study with diagnostic implications". Neurology. 58 (3): 354–61. doi:10.1212/wnl.58.3.354. PMID   11839832. S2CID   46463344.
  15. ↑ Noshir Mehta; George E. Maloney; Dhirendra S. Bana; Steven J. Scrivani (20 September 2011). Head, Face, and Neck Pain Science, Evaluation, and Management: An Interdisciplinary Approach. John Wiley & Sons. p. 199. ISBN   978-1-118-20995-0. Archived from the original on 14 February 2017.
  16. 1 2 3 4 Robbins, Matthew S. (2013). "The Psychiatric Comorbidities of Cluster Headache". Current Pain and Headache Reports. 17 (2): 313. doi:10.1007/s11916-012-0313-8. PMID   23296640. S2CID   35296409.
  17. ↑ The 5-Minute Sports Medicine Consult (2 ed.). Lippincott Williams & Wilkins. 2012. p. 87. ISBN   9781451148121. Archived from the original on 10 September 2017.
  18. ↑ Matharu M, Goadsby P (2001). "Cluster Headache". Practical Neurology. 1: 42. doi: 10.1046/j.1474-7766.2001.00505.x . S2CID   19601387.
  19. ↑ Matharu, Manjit S; Goadsby, Peter J (2014). "Cluster headache: Focus on emerging therapies". Expert Review of Neurotherapeutics. 4 (5): 895–907. doi:10.1586/14737175.4.5.895. PMID   15853515. S2CID   43918900.
  20. ↑ Goadsby P, Mitchell N (1999). "Cluster Headaches". Australian Broadcasting Corporation. Archived from the original on 22 September 2011.
  21. 1 2 3 4 5 6 "IHS Classification ICHD-3 3.1.2 Cluster headache". The International Headache Society. Archived from the original on 8 February 2024. Retrieved 8 February 2024.
  22. ↑ Liang, Jen-Feng; Chen, Yung-Tai; Fuh, Jong-Ling; Li, Szu-Yuan; Liu, Chia-Jen; Chen, Tzeng-Ji; Tang, Chao-Hsiun; Wang, Shuu-Jiun (2012). "Cluster headache is associated with an increased risk of depression: A nationwide population-based cohort study". Cephalalgia. 33 (3): 182–9. doi: 10.1177/0333102412469738 . PMID   23212294. S2CID   23184973.
  23. ↑ Jensen, RM; Lyngberg, A; Jensen, RH (2016). "Burden of Cluster Headache". Cephalalgia. 27 (6): 535–41. doi:10.1111/j.1468-2982.2007.01330.x. PMID   17459083. S2CID   38485245.
  24. ↑ Tabaee D., Payam; Rizzoli, P; Pecis, M (2020). "Right-to-left shunt and obstructive sleep apnea in cluster headache". Neurology & Neurosc. 1 (1): 1–3. Archived from the original on 24 October 2020. Retrieved 22 January 2021.
  25. ↑ Pringsheim, Tamara (2014). "Cluster Headache: Evidence for a Disorder of Circadian Rhythm and Hypothalamic Function". The Canadian Journal of Neurological Sciences. 29 (1): 33–40. doi: 10.1017/S0317167100001694 . PMID   11858532.
  26. ↑ Dodick, David W.; Eross, Eric J.; Parish, James M. (2003). "Clinical, Anatomical, and Physiologic Relationship Between Sleep and Headache". Headache: The Journal of Head and Face Pain. 43 (3): 282–92. doi:10.1046/j.1526-4610.2003.03055.x. PMID   12603650. S2CID   6029272.
  27. ↑ "Cluster headaches:Pattern of attacks". NHS. Gov.UK. 22 May 2017. Archived from the original on 20 June 2019. Retrieved 13 December 2018.
  28. ↑ Torelli, Paola; Manzoni, Gian Camillo (2002). "What predicts evolution from episodic to chronic cluster headache?". Current Pain and Headache Reports. 6 (1): 65–70. doi:10.1007/s11916-002-0026-5. PMID   11749880. S2CID   37173661.
  29. ↑ Headache Classification Committee of the International Headache Society (IHS) (2013). "The International Classification of Headache Disorders, 3rd edition (beta version)" (PDF). Cephalalgia. 33 (9): 629–808. doi:10.1177/0333102413485658. PMID   23771276. S2CID   78846027. Archived (PDF) from the original on 9 February 2020. Retrieved 16 August 2019.
  30. ↑ Ferraro S, Nigri A, Bruzzone MG, Demichelis G, Pinardi C, Brivio L, Giani L, Proietti A, Leone M, Chiapparini L (2019). "Cluster headache: insights from resting-state functional magnetic resonance imaging". Neurological Sciences. 40 (Suppl 1): 45–47. doi:10.1007/s10072-019-03874-8. PMID   30941629. S2CID   91190597.
  31. 1 2 3 Waung MW, Taylor A, Qualmann KJ, Burish MJ (2020). "Family History of Cluster HeadacheA Systematic Review". JAMA Neurology. 77 (7): 887–896. doi:10.1001/jamaneurol.2020.0682. PMC   7644512 . PMID   32310255.
  32. 1 2 Pinessi, L.; Rainero, I.; Rivoiro, C.; Rubino, E.; Gallone, S. (2005). "Genetics of cluster headache: An update". The Journal of Headache and Pain . 6 (4): 234–6. doi:10.1007/s10194-005-0194-x. PMC   3452030 . PMID   16362673.
  33. 1 2 3 O'Connor, Emer; Simpson, Benjamin S.; Houlden, Henry; Vandrovcova, Jana; Matharu, Manjit (25 April 2020). "Prevalence of familial cluster headache: a systematic review and meta-analysis". The Journal of Headache and Pain . 21 (1): 37. doi: 10.1186/s10194-020-01101-w . ISSN   1129-2377. PMC   7183702 . PMID   32334514.
  34. ↑ Schürks, Markus; Diener, Hans-Christoph (2008). "Cluster headache and lifestyle habits". Current Pain and Headache Reports. 12 (2): 115–21. doi:10.1007/s11916-008-0022-5. PMID   18474191. S2CID   29434840.
  35. ↑ Pringsheim, Tamara (February 2002). "Cluster headache: evidence for a disorder of circadian rhythm and hypothalamic function". Canadian Journal of Neurological Sciences. 29 (1): 33–40. doi: 10.1017/S0317167100001694 . PMID   11858532.
  36. ↑ Dasilva, Alexandre F. M.; Goadsby, Peter J.; Borsook, David (2007). "Cluster headache: A review of neuroimaging findings". Current Pain and Headache Reports. 11 (2): 131–6. doi:10.1007/s11916-007-0010-1. PMID   17367592. S2CID   35178080.
  37. ↑ "Headache diary: helping you manage your headache" (PDF). NPS.org.au. Archived from the original (PDF) on 21 September 2013. Retrieved 2 January 2014.
  38. ↑ Clarke, C E (2005). "Ability of a nurse specialist to diagnose simple headache disorders compared with consultant neurologists". Journal of Neurology, Neurosurgery & Psychiatry. 76 (8): 1170–2. doi:10.1136/jnnp.2004.057968. PMC   1739753 . PMID   16024902.
  39. ↑ Bahra, A.; Goadsby, P. J. (2004). "Diagnostic delays and mis-management in cluster headache". Acta Neurologica Scandinavica. 109 (3): 175–9. doi: 10.1046/j.1600-0404.2003.00237.x . PMID   14763953. S2CID   22500766.
  40. 1 2 Van Alboom, E; Louis, P; Van Zandijcke, M; Crevits, L; Vakaet, A; Paemeleire, K (2009). "Diagnostic and therapeutic trajectory of cluster headache patients in Flanders". Acta Neurologica Belgica. 109 (1): 10–7. PMID   19402567.
  41. 1 2 Tfelt-Hansen, Peer C.; Jensen, Rigmor H. (2012). "Management of Cluster Headache". CNS Drugs. 26 (7): 571–80. doi:10.2165/11632850-000000000-00000. PMID   22650381. S2CID   22522914.
  42. ↑ Klapper, Jack A.; Klapper, Amy; Voss, Tracy (2000). "The Misdiagnosis of Cluster Headache: A Nonclinic, Population-Based, Internet Survey". Headache. 40 (9): 730–5. doi:10.1046/j.1526-4610.2000.00127.x. PMID   11091291. S2CID   40116437.
  43. ↑ Prakash, Sanjay; Shah, Nilima D; Chavda, Bhavna V (2010). "Cluster headache responsive to indomethacin: Case reports and a critical review of the literature". Cephalalgia. 30 (8): 975–82. doi:10.1177/0333102409357642. PMID   20656709. S2CID   5938778.
  44. ↑ Sjaastad, O; Vincent, M (2010). "Indomethacin responsive headache syndromes: Chronic paroxysmal hemicrania and Hemicrania continua. How they were discovered and what we have learned since". Functional Neurology. 25 (1): 49–55. PMID   20626997.
  45. ↑ Sanjay Prakash; Nilima D Shah; Bhavna V Chavda (2010). "Cluster headache responsive to indomethacin: Case reports and a critical review of the literature". Cephalalgia. 30 (8): 975–982. doi:10.1177/0333102409357642. PMID   20656709. S2CID   5938778.
  46. ↑ Rizzoli, P; Mullally, WJ (September 2017). "Headache". American Journal of Medicine (Review). S0002-9343 (17): 30932–4. doi: 10.1016/j.amjmed.2017.09.005 . PMID   28939471.
  47. ↑ Benoliel, Rafael (2012). "Trigeminal autonomic cephalgias". British Journal of Pain. 6 (3): 106–23. doi:10.1177/2049463712456355. PMC   4590147 . PMID   26516482.
  48. ↑ Nalini Vadivelu; Alan David Kaye; Jack M. Berger (28 November 2012). Essentials of palliative care. New York, NY: Springer. p. 335. ISBN   9781461451648. Archived from the original on 10 September 2017.
  49. 1 2 3 May, A.; Leone, M.; Áfra, J.; Linde, M.; Sándor, P. S.; Evers, S.; Goadsby, P. J. (2006). "EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias". European Journal of Neurology. 13 (10): 1066–77. doi: 10.1111/j.1468-1331.2006.01566.x . PMID   16987158.
  50. 1 2 Petersen AS, Barloese MC, Snoer A, Soerensen AM, Jensen RH (2019). "Verapamil and Cluster Headache: Still a Mystery. A Narrative Review of Efficacy, Mechanisms and Perspectives". Headache. 59 (8): 1198–1211. doi:10.1111/head.13603. PMID   31339562. S2CID   198193843.
  51. 1 2 Butticè, Claudio (2022). What you need to know about headaches. Santa Barbara, California: Greenwood. ISBN   978-1-4408-7531-1. OCLC   1259297708. Archived from the original on 28 November 2022. Retrieved 19 September 2022.
  52. ↑ Magis, Delphine; Schoenen, Jean (2011). "Peripheral Nerve Stimulation in Chronic Cluster Headache". Peripheral Nerve Stimulation. Progress in Neurological Surgery. Vol. 24. pp. 126–32. doi:10.1159/000323045. ISBN   978-3-8055-9489-9. PMID   21422783.
  53. 1 2 3 4 5 Martelletti, Paolo; Jensen, Rigmor H; Antal, Andrea; Arcioni, Roberto; Brighina, Filippo; De Tommaso, Marina; Franzini, Angelo; Fontaine, Denys; Heiland, Max; Jürgens, Tim P; Leone, Massimo; Magis, Delphine; Paemeleire, Koen; Palmisani, Stefano; Paulus, Walter; May, Arne (2013). "Neuromodulation of chronic headaches: Position statement from the European Headache Federation". The Journal of Headache and Pain . 14 (1): 86. doi: 10.1186/1129-2377-14-86 . PMC   4231359 . PMID   24144382.
  54. ↑ Bartsch, Thorsten; Paemeleire, Koen; Goadsby, Peter J (2009). "Neurostimulation approaches to primary headache disorders". Current Opinion in Neurology. 22 (3): 262–8. doi:10.1097/wco.0b013e32832ae61e. PMID   19434793. S2CID   2063863.
  55. ↑ Evers, Stefan (2010). "Pharmacotherapy of cluster headache". Expert Opinion on Pharmacotherapy. 11 (13): 2121–7. doi:10.1517/14656566.2010.496454. PMID   20569084. S2CID   40081324.
  56. 1 2 Matharu M (9 February 2010). "Cluster headache". Clinical Evidence (Review). 2010. PMC   2907610 . PMID   21718584.
  57. ↑ Ailani, Jessica; Young, William B. (2009). "The role of nerve blocks and botulinum toxin injections in the management of cluster headaches". Current Pain and Headache Reports. 13 (2): 164–7. doi:10.1007/s11916-009-0028-7. PMID   19272284. S2CID   10284630.
  58. 1 2 Bennett, Michael H; French, Christopher; Schnabel, Alexander; Wasiak, Jason; Kranke, Peter; Weibel, Stephanie (2015). "Normobaric and hyperbaric oxygen therapy for the treatment and prevention of migraine and cluster headache". Cochrane Database of Systematic Reviews. Vol. 2016. pp. CD005219. doi:10.1002/14651858.CD005219.pub3. PMC   8720466 . PMID   26709672.
  59. ↑ "Cluster headache". MedlinePlus Medical Encyclopedia. 2 November 2012. Archived from the original on 5 April 2014. Retrieved 5 April 2014.
  60. 1 2 Law, Simon; Derry, Sheena; Moore, R Andrew (2013). "Triptans for acute cluster headache". Cochrane Database of Systematic Reviews. Vol. 2018. pp. CD008042. doi:10.1002/14651858.cd008042.pub3. PMC   4170909 . PMID   20393964.
  61. 1 2 Paemeleire, Koen; Evers, Stefan; Goadsby, Peter J. (2008). "Medication-overuse headache in patients with cluster headache". Current Pain and Headache Reports. 12 (2): 122–7. doi:10.1007/s11916-008-0023-4. PMID   18474192. S2CID   28752169.
  62. ↑ Johnson, Jacinta L; Hutchinson, Mark R; Williams, Desmond B; Rolan, Paul (2012). "Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment". Cephalalgia. 33 (1): 52–64. doi:10.1177/0333102412467512. hdl: 2440/78280 . PMID   23144180. S2CID   5697283.
  63. ↑ Watkins, Linda R.; Hutchinson, Mark R.; Rice, Kenner C.; Maier, Steven F. (2009). "The "Toll" of Opioid-Induced Glial Activation: Improving the Clinical Efficacy of Opioids by Targeting Glia". Trends in Pharmacological Sciences. 30 (11): 581–91. doi:10.1016/j.tips.2009.08.002. PMC   2783351 . PMID   19762094.
  64. ↑ Saper, Joel R.; Da Silva, Arnaldo Neves (2013). "Medication Overuse Headache: History, Features, Prevention and Management Strategies". CNS Drugs. 27 (11): 867–77. doi:10.1007/s40263-013-0081-y. PMID   23925669. S2CID   39617729.
  65. ↑ Matharu, M (2010). "Cluster headache". BMJ Clinical Evidence. 2010. PMC   2907610 . PMID   21718584.
  66. ↑ Malu, Omojo Odihi; Bailey, Jonathan; Hawks, Matthew Kendall (January 2022). "Cluster Headache: Rapid Evidence Review". American Family Physician. 105 (1): 24–32. ISSN   1532-0650. PMID   35029932. Archived from the original on 30 October 2022. Retrieved 30 October 2022.
  67. ↑ Ishaq Abu-Arafeh; Aynur Özge (2016). Headache in Children and Adolescents: A Case-Based Approach. Springer International Publishing Switzerland. p. 62. ISBN   978-3-319-28628-0. Archived from the original on 10 September 2017.
  68. ↑ Harris W.: Neuritis and Neuralgia. p. 307-12. Oxford: Oxford University Press 1926.
  69. ↑ Bickerstaff E (1959). "The periodic migrainous neuralgia of Wilfred Harris". The Lancet. 273 (7082): 1069–71. doi:10.1016/S0140-6736(59)90651-8. PMID   13655672.
  70. ↑ Boes, CJ; Capobianco, DJ; Matharu, MS; Goadsby, PJ (2016). "Wilfred Harris' Early Description of Cluster Headache". Cephalalgia. 22 (4): 320–6. doi:10.1046/j.1468-2982.2002.00360.x. PMID   12100097. S2CID   25747361.
  71. ↑ Pearce, J M S (2007). "Gerardi van Swieten: Descriptions of episodic cluster headache". Journal of Neurology, Neurosurgery & Psychiatry. 78 (11): 1248–9. doi:10.1136/jnnp.2007.123091. PMC   2117620 . PMID   17940171.
  72. ↑ Horton BT, MacLean AR, Craig WM (1939). "A new syndrome of vascular headache: results of treatment with histamine: preliminary report". Mayo Clinic Proceedings. 14: 257.
  73. ↑ Silberstein SD, Lipton RB, Goadsby PJ (2002). Headache in Clinical Practice (Second ed.). Taylor & Francis.[ page needed ]
  74. ↑ Johnson, Tim (16 May 2013). "Researcher works to unlock mysteries of migraines". USA Today. Archived from the original on 17 May 2013. Retrieved 4 January 2013.
  75. 1 2 Sun-Edelstein, Christina; Mauskop, Alexander (2011). "Alternative Headache Treatments: Nutraceuticals, Behavioral and Physical Treatments". Headache. 51 (3): 469–83. doi: 10.1111/j.1526-4610.2011.01846.x . PMID   21352222.
  76. ↑ Vollenweider, Franz X.; Kometer, Michael (2010). "The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders". Nature Reviews Neuroscience. 11 (9): 642–51. doi:10.1038/nrn2884. PMID   20717121. S2CID   16588263.
  77. ↑ Brandt, Roemer B.; Doesborg, Patty G. G.; Haan, Joost; Ferrari, Michel D.; Fronczek, Rolf (1 February 2020). "Pharmacotherapy for Cluster Headache". CNS Drugs. 34 (2): 171–184. doi: 10.1007/s40263-019-00696-2 . ISSN   1179-1934. PMC   7018790 . PMID   31997136.
  78. ↑ "Psilocybin for the Treatment of Cluster Headache - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Archived from the original on 27 May 2020. Retrieved 15 February 2020.
  79. ↑ "A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)". ClinicalTrials.gov. 28 January 2021. Archived from the original on 3 May 2020. Retrieved 30 November 2017.
  80. ↑ "A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)". ClinicalTrials.gov. 2 July 2020. Archived from the original on 1 May 2020. Retrieved 30 November 2017.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.